NASDAQ$BCPC

Balchem Corporation · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Balchem reported a solid Q4 2023, marked by record adjusted EBITDA and strong free cash flow, despite demand challenges in some areas. The Human Nutrition and Health segment achieved record sales and earnings.

Balchem Corporation reported Q4 2023 results with net sales of $228.7 million, net earnings of $26.6 million, adjusted EBITDA of $55.4 million, and free cash flow of $56.0 million. The Human Nutrition and Health segment had record sales and earnings.

  • GAAP net earnings increased by 24.5% year-over-year to $26.6 million.
  • Adjusted EBITDA increased by 5.4% year-over-year to $55.4 million.
  • Record free cash flow of $56.0 million, up 103.4% from the prior year quarter.
  • Record Human Nutrition & Health segment sales of $138.0 million, up 5.8% year-over-year, with record earnings from operations of $25.2 million, up 43.8%.

Headline financials

Total Revenue

$229M

Previous: $233M-1.6%
EPS (adj)

$0.83

Previous: $0.67+23.9%
Capital Expenditures

-$11.6M

Previous: $14.1M-181.9%
Net Income

$26.6M

Previous: $21.4M+24.5%
Operating Income

$38.3M

Previous: $33.3M+15.1%
Gross Profit

$75M

Previous: $68.6M+9.3%
Stock-Based Comp

$3.79M

Previous: $3.39M+11.8%

Revenue & EPS history

Balchem · Revenue · Quarterly

$229M

Q4 2023-1.6%vs Q4 2022
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

Balchem · $228M total across 3 segments · Q3 2023

  • Human Nutrition & Health
    $144M+1.3%
  • Animal Nutrition & Health
    $53.9M-17.8%
  • Specialty Products
    $30M+1.2%

Forward guidance

Balchem is well positioned to deliver top and bottom line growth on a full year basis, while continuing to advance strategic growth initiatives.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.0%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+0.9%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+25.0%

Q1 2014

Best reaction

-16.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-6.8%-7.0%-9.7%
Q4 2025-2.3%+2.6%-7.4%
Q3 2025+4.1%+3.9%+1.3%
Q1 2025-2.6%-1.5%+4.8%
Q4 2024+1.5%+7.0%-0.1%
Q3 2024+2.8%+1.6%+9.8%
Q2 2024+3.9%+1.5%-1.2%
Q1 2024-1.8%-3.0%-8.8%
Q4 2023+7.4%+5.0%+6.8%
Q3 2023-5.0%-4.1%+1.1%
Q2 2023+4.8%+5.0%+7.1%
Q1 2023+1.7%+0.5%+5.2%
Q4 2022-2.0%-0.2%-7.7%
Q3 2022-0.6%-0.5%+5.4%
Q2 2022-5.2%-6.6%+2.3%
Q1 2022+1.6%-0.9%-10.5%
Q4 2021+1.0%-0.7%+1.2%
Q3 2021-0.8%+2.3%+7.9%
Q2 2021-0.8%-2.5%+2.7%
Q1 2021-0.2%-0.1%+0.5%
Q4 2020+5.4%+6.4%+10.7%
Q3 2020-1.7%-0.5%+3.3%
Q2 2020+4.6%+4.7%+0.3%
Q1 2020-5.4%-3.9%-9.3%
Q4 2019-10.7%-13.3%-15.9%
Q3 2019+2.9%+1.2%-0.8%
Q2 2019-16.3%-15.9%-13.5%
Q1 2019+1.1%+4.0%+9.4%
Q4 2018+8.0%+12.4%+10.7%
Q3 2018-4.9%-4.9%-13.7%
Q2 2018+1.1%+1.3%+10.1%
Q1 2018-1.3%+2.2%+7.9%
Q4 2017+2.3%+5.9%+8.6%
Q3 2017+1.0%-0.7%+1.3%
Q2 2017-2.6%-3.9%-1.8%
Q1 2017-3.3%-5.3%-1.8%
Q4 2016+5.2%+2.2%-2.5%
Q3 2016-4.5%+0.8%+12.3%
Q2 2016+1.3%+2.0%+8.7%
Q1 2016+0.3%
Q4 2015-0.4%
Q3 2015-2.0%
Q2 2015+5.2%
Q1 2015-0.5%
Q4 2014-3.4%
Q3 2014+6.7%
Q2 2014+2.5%
Q1 2014+25.0%
Q4 2013+0.4%
Q3 2013-4.9%
Q2 2013+1.3%
Q1 2013-2.3%
Q4 2012+0.8%
Q3 2012-10.5%
Q2 2012+5.9%
Q1 2011+2.1%
Q4 2011+2.1%
Q1 2012+2.4%
Q1 2010-4.1%
Q4 2009-4.1%
Q3 2010-3.2%
Q3 2011-3.2%
Q2 2011+1.0%
Q4 2010+1.0%
Q2 2010+1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro